Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 457 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control (plasma) Clear all
Not listed Not applicable Interventional

Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Validation Study

NCT05870943
View directory record Official record
Conditions
Obesity
Interventions
Hybrid Argon Plasma Coagulation, Endoscopic Sleeve Gastroplasty
Procedure
Lead sponsor
True You Weight Loss
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 5, 2026, 11:56 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

NCT05060848
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
55 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

NCT01721226
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention
Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 5, 2026, 11:56 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

NCT00000897
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

NCT01117350
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects

NCT01591148
View directory record Official record
Conditions
Morbid Obesity
Interventions
propofol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

NCT00236080
View directory record Official record
Conditions
Chronic Shift Work Sleep Disorder
Interventions
PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg, Armodafinil 150 mg, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 5, 2026, 11:56 AM EDT
Terminated Phase 4 Interventional Results available

IV Lidocaine in Pediatric AIS

NCT03893318
View directory record Official record
Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
IV lidocaine, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

NCT02001688
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Kamada-AAT for Inhalation, 80mg, Placebo, Kamada-AAT for Inhalation, 160mg
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 5, 2026, 11:56 AM EDT
Completed No phase listed Observational

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

NCT04407481
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Interventions
Panzyga, Placebo
Biological · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
St. Petersburg, Florida • Columbus, Georgia • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Ultrasound-guided Rectus Sheath Block for Post-operative Pain Control Following Umbilical Hernia Repair

NCT00836134
View directory record Official record
Conditions
Pain
Interventions
rectus sheath block, local anesthetic infiltration
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks

NCT00373399
View directory record Official record
Conditions
Marijuana Use Disorder
Interventions
Inactive Marijuana (0% THC), Low THC marijuana (1.8 %THC), High THC marijuana (3.9% THC)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 2Phase 3 Interventional

Cyrotherapy vs. APC in GAVE

NCT00587405
View directory record Official record
Conditions
Watermelon Stomach
Interventions
cryotherapy, Argon Plasma Coagulation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 5, 2026, 11:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Small Extracellular Vesicles and Insulin Action

NCT05933707
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolically Healthy Obesity, Obesity, Metabolically Benign
Interventions
People with Metabolically Unhealthy Obesity - Low Calorie Diet
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

NCT01795339
View directory record Official record
Conditions
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Sep 5, 2026, 11:56 AM EDT
Recruiting Phase 3 Interventional

Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass

NCT06702553
View directory record Official record
Conditions
Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
Nitric Oxide Gas, Standard Care Arm
Drug
Lead sponsor
Xijing Hospital
Other
Eligibility
18 Years and older
Enrollment
3,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

NCT04717726
View directory record Official record
Conditions
Obesity
Interventions
Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON)
Dietary Supplement · Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 5, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

NCT04362176
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV-2
Interventions
pathogen reduced SARS-CoV-2 convalescent plasma, Placebo
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 5, 2026, 11:56 AM EDT